Audrey Grenier1,2, Patrice Brassard1,3, Olivier F Bertrand1, Jean-Pierre Després1,3, Olivier Costerousse1, Natalie Alméras1, Et Paul Poirier4,5. 1. Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, QC, Canada. 2. Faculty of pharmacy, Laval University, Quebec City, QC, Canada. 3. Department of Kinesiology, Faculty of Medicine, Laval University, Quebec City, QC, Canada. 4. Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, QC, Canada. paul.poirier@criucpq.ulaval.ca. 5. Faculty of pharmacy, Laval University, Quebec City, QC, Canada. paul.poirier@criucpq.ulaval.ca.
Abstract
INTRODUCTION: Obesity is associated with decreased heart rate variability (HRV). Rosiglitazone, a PPARγ agonist, is generally associated with increases in body mass. PURPOSE: To assess whether the gain in body mass and adiposity expected from rosiglitazone treatment has an influence on HRV in patients with type 2 diabetes and coronary artery disease. METHODS:One hundred and twenty-five patients with type 2 diabetes and coronary artery disease aged between 40 and 75 years were studied. Anthropometric measurements: (1) body mass index (BMI), (2) waist circumference (WC), (3) abdominal computed tomography (CT) scan, and HRV (using a 24 h Holter) were measured at baseline and after 12 months of treatment. Patients were randomized to rosiglitazone or placebo regimen. RESULTS: In the rosiglitazone vs. placebo group, there were significant increases in body mass [3.5 (2.6;4.4); mean (95 % CI) vs. 0.2 (-0.4;0.8)] kg), BMI [1.3 (1.0;1.6) vs. 0.1 (-0.1;0.3) kg/m2], WC [2.1 (0.9;3.3) vs. 0.4 (-0.4;1.2) cm, all p ≤ 0.001] and subcutaneous adipose tissue [253 (187;319) vs. 6 (-24;36) cm3, p ≤ 0.001] without statistically significant changes in visceral adipose tissue [-22 (-91;47) vs. 57 (43;71) cm3, p = 0.546], respectively. There was no change in HRV in either group after 12 months. There were no correlations between changes in HRV variables and fat distribution. CONCLUSION: Our results suggest that changes in adiposity indices observed after 12 months of rosiglitazone therapy have no deleterious influence on HRV in patients with type 2 diabetes and coronary artery disease.
RCT Entities:
INTRODUCTION: Obesity is associated with decreased heart rate variability (HRV). Rosiglitazone, a PPARγ agonist, is generally associated with increases in body mass. PURPOSE: To assess whether the gain in body mass and adiposity expected from rosiglitazone treatment has an influence on HRV in patients with type 2 diabetes and coronary artery disease. METHODS: One hundred and twenty-five patients with type 2 diabetes and coronary artery disease aged between 40 and 75 years were studied. Anthropometric measurements: (1) body mass index (BMI), (2) waist circumference (WC), (3) abdominal computed tomography (CT) scan, and HRV (using a 24 h Holter) were measured at baseline and after 12 months of treatment. Patients were randomized to rosiglitazone or placebo regimen. RESULTS: In the rosiglitazone vs. placebo group, there were significant increases in body mass [3.5 (2.6;4.4); mean (95 % CI) vs. 0.2 (-0.4;0.8)] kg), BMI [1.3 (1.0;1.6) vs. 0.1 (-0.1;0.3) kg/m2], WC [2.1 (0.9;3.3) vs. 0.4 (-0.4;1.2) cm, all p ≤ 0.001] and subcutaneous adipose tissue [253 (187;319) vs. 6 (-24;36) cm3, p ≤ 0.001] without statistically significant changes in visceral adipose tissue [-22 (-91;47) vs. 57 (43;71) cm3, p = 0.546], respectively. There was no change in HRV in either group after 12 months. There were no correlations between changes in HRV variables and fat distribution. CONCLUSION: Our results suggest that changes in adiposity indices observed after 12 months of rosiglitazone therapy have no deleterious influence on HRV in patients with type 2 diabetes and coronary artery disease.
Authors: Jean-Pierre Després; Isabelle Lemieux; Jean Bergeron; Philippe Pibarot; Patrick Mathieu; Eric Larose; Josep Rodés-Cabau; Olivier F Bertrand; Paul Poirier Journal: Arterioscler Thromb Vasc Biol Date: 2008-03-20 Impact factor: 8.311
Authors: Nora E Straznicky; Mariee T Grima; Carolina I Sari; Nina Eikelis; Gavin W Lambert; Paul J Nestel; Sofie Karapanagiotidis; Chiew Wong; Katrina Richards; Petra Marusic; John B Dixon; Markus P Schlaich; Elisabeth A Lambert Journal: J Clin Endocrinol Metab Date: 2014-06-17 Impact factor: 5.958
Authors: Olivier F Bertrand; Paul Poirier; Josep Rodés-Cabau; Stéphane Rinfret; Lawrence Title; Vladimir Dzavik; Madhu Natarajan; Juan Angel; Nuria Batalla; Natalie Alméras; Olivier Costerousse; Robert De Larochellière; Louis Roy; Jean-Pierre Després Journal: Can J Cardiol Date: 2009-09 Impact factor: 5.223
Authors: B Gwen Windham; Stefano Fumagalli; Alessandro Ble; John J Sollers; Julian F Thayer; Samar S Najjar; Michael E Griswold; Luigi Ferrucci Journal: J Obes Date: 2012-05-09
Authors: Ian J Neeland; Colby R Ayers; Anand K Rohatgi; Aslan T Turer; Jarett D Berry; Sandeep R Das; Gloria L Vega; Amit Khera; Darren K McGuire; Scott M Grundy; James A de Lemos Journal: Obesity (Silver Spring) Date: 2013-05-19 Impact factor: 5.002